EA201590391A1 - Пиразолилмочевины в качестве ингибиторов киназы - Google Patents

Пиразолилмочевины в качестве ингибиторов киназы

Info

Publication number
EA201590391A1
EA201590391A1 EA201590391A EA201590391A EA201590391A1 EA 201590391 A1 EA201590391 A1 EA 201590391A1 EA 201590391 A EA201590391 A EA 201590391A EA 201590391 A EA201590391 A EA 201590391A EA 201590391 A1 EA201590391 A1 EA 201590391A1
Authority
EA
Eurasian Patent Office
Prior art keywords
utie
pyrazolyl
kinase inhibitors
kinases
inflammatory diseases
Prior art date
Application number
EA201590391A
Other languages
English (en)
Other versions
EA025393B1 (ru
Inventor
Клэр Энн Мари Кариу
Кэтрин Элизабет Чаррон
Юэн Александер Фрэйзер Фордайс
Дэниел Хамза
Мэттью Колин Тор Файф
Кадзухиро Ито
Джон Кинг-Андервуд
Питер Джон Мюррей
Стюарт Томас Онионз
Стефен Малкольм Том
Хейли Теган Анджела Уотсон
Джонатан Гарет Уилльямс
Original Assignee
Респайверт Лимитед
Топайверт Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Респайверт Лимитед, Топайверт Фарма Лимитед filed Critical Респайверт Лимитед
Publication of EA201590391A1 publication Critical patent/EA201590391A1/ru
Publication of EA025393B1 publication Critical patent/EA025393B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предоставлены соединения формулы Iгде R, R, R, R, Q, X и Y имеют значения, приведенные в описании изобретения, которые обладают противовоспалительной активностью (например, в результате ингибирования ими одного или более представителей семейства ферментов р38 митоген-активируемых протеинкиназ; Syk киназы; и представителей Src семейства тирозинкиназ) и применяются в терапии, в том числе в фармацевтических комбинациях, в частности, при лечении воспалительных заболеваний, включая воспалительные заболевания легких, глаз и кишечника.
EA201590391A 2012-08-17 2013-08-16 Пиразолилмочевины в качестве ингибиторов киназы EA025393B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1214750.0A GB201214750D0 (en) 2012-08-17 2012-08-17 Compounds
US201361782793P 2013-03-14 2013-03-14
PCT/GB2013/052184 WO2014027209A1 (en) 2012-08-17 2013-08-16 Pyrazolyl-ureas as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201590391A1 true EA201590391A1 (ru) 2015-06-30
EA025393B1 EA025393B1 (ru) 2016-12-30

Family

ID=47016978

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590391A EA025393B1 (ru) 2012-08-17 2013-08-16 Пиразолилмочевины в качестве ингибиторов киназы

Country Status (12)

Country Link
US (2) US9701670B2 (ru)
EP (1) EP2885284B1 (ru)
JP (1) JP2015524837A (ru)
KR (1) KR20150056777A (ru)
CN (1) CN105073725A (ru)
AU (1) AU2013303922A1 (ru)
BR (1) BR112015003218A2 (ru)
CA (1) CA2881914A1 (ru)
EA (1) EA025393B1 (ru)
GB (1) GB201214750D0 (ru)
MX (1) MX2015002044A (ru)
WO (1) WO2014027209A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534904T3 (es) * 2003-01-22 2015-04-30 Senju Pharmaceutical Co., Ltd. Preparación de absorción percutánea para el tratamiento de enfermedad oftálmica, uso del mismo y método para la migración del remedio oftálmico en el tejido tópico en los ojos
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
AU2011209586B2 (en) 2010-02-01 2016-01-21 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy
ES2583853T3 (es) 2011-10-03 2016-09-22 Respivert Limited 1-Pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de p38 MAP cinasa
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2890695A2 (en) 2012-08-29 2015-07-08 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2925742B1 (en) 2012-11-16 2016-10-26 Respivert Limited Kinase inhibitors
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
CN105246884B (zh) * 2013-04-02 2018-05-22 瑞斯比维特有限公司 用作激酶抑制剂的脲衍生物
US9771353B2 (en) * 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
JP6514703B2 (ja) 2013-12-20 2019-05-15 トピバート ファーマ リミテッド キナーゼインヒビターとして有用な尿素誘導体
MX371353B (es) 2014-02-14 2020-01-27 Respivert Ltd Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
US20180177718A1 (en) * 2015-05-29 2018-06-28 Envisia Therapeutics, Inc. Implant for treatment of an ocular condition
UA127863C2 (uk) * 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
KR102387073B1 (ko) 2016-04-06 2022-04-15 옥슬러 액퀴지션즈 리미티드 키나제 저해제
JP2019515925A (ja) * 2016-04-29 2019-06-13 エンセラドゥス ファーマセウティカルス べー．フェー． 炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド
CN106771117B (zh) * 2016-11-25 2018-09-14 王婧 一种中性粒细胞抗原底片的制备方法
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155817T3 (es) 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
ES2155045T3 (es) 1997-12-22 2007-02-01 Bayer Pharmaceuticals Corp. Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2001004115A2 (en) 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
JP4955171B2 (ja) 1999-11-16 2012-06-20 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての尿素誘導体
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
ES2299689T3 (es) 2002-02-25 2008-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas.
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
MX2007001759A (es) 2004-08-12 2007-04-20 Pfizer Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos.
GB0500435D0 (en) 2005-01-10 2005-02-16 Novartis Ag Organic compounds
AR058128A1 (es) 2005-10-28 2008-01-23 Lilly Co Eli Compuesto de pirazolil carbamato y formulacion farmaceutica que lo comprende
DK2268623T3 (en) 2008-03-17 2015-06-29 Ambit Biosciences Corp QUINAZOLINE DERIVATIVES AS RAF CHINESE MODULATORS AND PROCEDURES FOR USE THEREOF
NZ591427A (en) 2008-10-02 2012-12-21 Respivert Ltd P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
NZ593104A (en) 2008-12-11 2012-11-30 Respivert Ltd P38 map kinase inhibitors
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
WO2010072155A1 (zh) 2008-12-26 2010-07-01 复旦大学 一种嘧啶类衍生物及其制备方法和用途
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
ES2590347T3 (es) 2010-03-15 2016-11-21 Ube Industries, Ltd. Método para producir un compuesto de amida
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
EP2556068B1 (en) * 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Methods
WO2011158044A2 (en) 2010-06-17 2011-12-22 Respivert Limited Respiratory formulations and compounds for use therein
ES2583853T3 (es) 2011-10-03 2016-09-22 Respivert Limited 1-Pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de p38 MAP cinasa
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
EP2788349B1 (en) 2011-12-09 2016-10-26 Chiesi Farmaceutici S.p.A. Kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
EP2890695A2 (en) 2012-08-29 2015-07-08 Respivert Limited Kinase inhibitors
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2925742B1 (en) 2012-11-16 2016-10-26 Respivert Limited Kinase inhibitors
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
CN105246884B (zh) 2013-04-02 2018-05-22 瑞斯比维特有限公司 用作激酶抑制剂的脲衍生物
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
MX371353B (es) 2014-02-14 2020-01-27 Respivert Ltd Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38

Also Published As

Publication number Publication date
WO2014027209A1 (en) 2014-02-20
AU2013303922A1 (en) 2015-02-19
US9701670B2 (en) 2017-07-11
BR112015003218A2 (pt) 2019-09-24
US20140057915A1 (en) 2014-02-27
EP2885284A1 (en) 2015-06-24
KR20150056777A (ko) 2015-05-27
GB201214750D0 (en) 2012-10-03
EP2885284B1 (en) 2016-11-02
CA2881914A1 (en) 2014-02-20
MX2015002044A (es) 2016-01-22
EA025393B1 (ru) 2016-12-30
CN105073725A (zh) 2015-11-18
US20150218137A1 (en) 2015-08-06
JP2015524837A (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
EA201590391A1 (ru) Пиразолилмочевины в качестве ингибиторов киназы
EA201790658A1 (ru) Производные диарилмочевины в качестве ингибиторов киназы p38
EA201591907A1 (ru) Ингибитор киназ
WO2014033447A3 (en) Diaryl urea derivatives as p38 map kinase inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
EA201490949A1 (ru) Ингибиторы киназ
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
EA201390736A1 (ru) Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA023222B8 (ru) Пиразолилхиноксалиновые ингибиторы киназы
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201390520A1 (ru) Замещенные соединения пиридазинкарбоксамида
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний
NZ702253A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EA201892213A1 (ru) Ингибиторы киназ
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak
MY192305A (en) Bipyrazole derivatives as jak inhibitors
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA202090672A2 (ru) ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU